APO-VALSARTAN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

VALSARTAN

から入手可能:

APOTEX INC

ATCコード:

C09CA03

INN（国際名）:

VALSARTAN

投薬量:

80MG

医薬品形態:

TABLET

構図:

VALSARTAN 80MG

投与経路:

ORAL

パッケージ内のユニット:

30

処方タイプ:

Prescription

治療領域:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

製品概要:

Active ingredient group (AIG) number: 0131885001; AHFS:

認証ステータス:

MARKETED

承認日:

2012-07-12

製品の特徴

_APO-VALSARTAN Tablets Product Monograph_
_ _Page 1 of 41
PRODUCT MONOGRAPH
PR
APO-VALSARTAN
(VALSARTAN)
40 MG, 80 MG, 160 MG AND 320 MG TABLETS
Angiotensin II AT
1
Receptor Blocker
APOTEX INC. DATE OF REVISION:
150 SIGNET DRIVE SEPTEMBER 16, 2015
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER: 187072
_APO-VALSARTAN Tablets Product Monograph_
_ _Page 2 of 41
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTION
.........................................................................................
4
ADVERSE REACTIONS
......................................................................................................
8
DRUG INTERACTIONS
......................................................................................................12
DOSAGE AND ADMINISTRATION
.....................................................................................14
OVERDOSAGE
...................................................................................................................16
ACTION AND CLINICAL PHARMACOLOGY
......................................................................16
STORAGE AND
STABILITY................................................................................................19
SPECIAL HANDLING INSTRUCTIONS
..............................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................19
PART II: SCIENTIFIC INFORMATION
....................................................................................21
PHARMACEUTICAL INFORMATION
...................................